6EPL

Ras guanine exchange factor SOS1 (Rem-cdc25) in complex with KRAS(G12C)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.55 Å
  • R-Value Free: 0.224 
  • R-Value Work: 0.190 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.

Hillig, R.C.Sautier, B.Schroeder, J.Moosmayer, D.Hilpmann, A.Stegmann, C.M.Werbeck, N.D.Briem, H.Boemer, U.Weiske, J.Badock, V.Mastouri, J.Petersen, K.Siemeister, G.Kahmann, J.D.Wegener, D.Bohnke, N.Eis, K.Graham, K.Wortmann, L.von Nussbaum, F.Bader, B.

(2019) Proc. Natl. Acad. Sci. U.S.A. 116: 2551-2560

  • DOI: 10.1073/pnas.1812963116
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Since the late 1980s, mutations in the <i>RAS </i> genes have been recognized as major oncogenes with a high occurrence rate in human cancers. Such mutations reduce the ability of the small GTPase RAS to hydrolyze GTP, keeping this molecular switch ...

    Since the late 1980s, mutations in the RAS genes have been recognized as major oncogenes with a high occurrence rate in human cancers. Such mutations reduce the ability of the small GTPase RAS to hydrolyze GTP, keeping this molecular switch in a constitutively active GTP-bound form that drives, unchecked, oncogenic downstream signaling. One strategy to reduce the levels of active RAS is to target guanine nucleotide exchange factors, which allow RAS to cycle from the inactive GDP-bound state to the active GTP-bound form. Here, we describe the identification of potent and cell-active small-molecule inhibitors which efficiently disrupt the interaction between KRAS and its exchange factor SOS1, a mode of action confirmed by a series of biophysical techniques. The binding sites, mode of action, and selectivity were elucidated using crystal structures of KRAS G12C -SOS1, SOS1, and SOS2. By preventing formation of the KRAS-SOS1 complex, these inhibitors block reloading of KRAS with GTP, leading to antiproliferative activity. The final compound 23 (BAY-293) selectively inhibits the KRAS-SOS1 interaction with an IC 50 of 21 nM and is a valuable chemical probe for future investigations.


    Organizational Affiliation

    Drug Discovery Services, Evotec AG, 22419 Hamburg, Germany.,Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany; roman.hillig@bayer.com benjamin.bader@bayer.com.,Research and Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
GTPase KRas
R
170Homo sapiensMutation(s): 5 
Gene Names: KRAS (KRAS2, RASK2)
Find proteins for P01116 (Homo sapiens)
Go to Gene View: KRAS
Go to UniProtKB:  P01116
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Son of sevenless homolog 1
S
487Homo sapiensMutation(s): 1 
Gene Names: SOS1
Find proteins for Q07889 (Homo sapiens)
Go to Gene View: SOS1
Go to UniProtKB:  Q07889
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
GOL
Query on GOL

Download SDF File 
Download CCD File 
R
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.55 Å
  • R-Value Free: 0.224 
  • R-Value Work: 0.190 
  • Space Group: I 4 2 2
Unit Cell:
Length (Å)Angle (°)
a = 149.522α = 90.00
b = 149.522β = 90.00
c = 202.101γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
XDSdata reduction
REFMACrefinement
XDSdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2019-02-06
    Type: Initial release
  • Version 1.1: 2019-02-20
    Type: Data collection, Database references